Securities code: 688606 securities abbreviation: Hangzhou Alltest Biotech Co.Ltd(688606) Announcement No.: 2022-004
Hangzhou Alltest Biotech Co.Ltd(688606)
Stock trading abnormal fluctuation announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual joint and several liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
● Hangzhou Alltest Biotech Co.Ltd(688606) (hereinafter referred to as “the company”) shares fell by more than 30% from the daily closing price in three consecutive trading days on January 17, January 18 and January 19, 2022, According to the relevant provisions of the trading rules of Shanghai Stock Exchange, the special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange and the detailed rules for real-time monitoring of abnormal stock trading on the science and Innovation Board of Shanghai Stock Exchange (for Trial Implementation), it belongs to abnormal fluctuations in stock trading.
● after the company’s self-examination and written verification to the controlling shareholder and actual controller, as of the disclosure date of this announcement, it is confirmed that there are no major events or important information that should be disclosed but not disclosed.
● as of January 19, 2022, the closing price of the company was 161.50 yuan / share. According to the data released by China Securities Index Co., Ltd. on January 19, 2022, the latest rolling P / E ratio of the company is 12.63 times, the average rolling P / E ratio of the pharmaceutical manufacturing industry in which the company is located in the latest month is 32.24 times, and the P / E ratio of the company is lower than that of the industry. The company specially reminds investors to pay attention to investment risks, make rational decisions and invest prudently.
1、 Details of abnormal fluctuations in stock trading
The daily closing price of the company’s shares fell by more than 30% in three consecutive trading days on January 17, January 18 and January 19, 2022. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange and rules for real-time monitoring of abnormal stock trading on the science and Innovation Board of Shanghai Stock Exchange (Trial), It belongs to abnormal fluctuation of stock trading. 2、 Relevant information concerned and verified by the company
(I) production and operation.
According to the company’s self inspection, the company’s current production and operation activities are normal. The market environment and industrial policies have not been significantly adjusted, production costs and sales have not fluctuated significantly, and the internal production and operation order is normal.
(II) major events.
After the company’s self-examination and verification by letter to the controlling shareholder and actual controller of the company, as of the disclosure date of this announcement, except for the matters disclosed by the company, the controlling shareholder and actual controller of the company have no major matters affecting the abnormal fluctuation of the company’s stock trading; There is no other material information that should be disclosed but not disclosed by the company, including but not limited to planning major events involving mergers and acquisitions, share issuance, debt restructuring, business restructuring, asset divestiture and asset injection of listed companies.
(III) media reports, market rumors and hot concepts.
According to the company’s self-examination, the company did not find any media reports and market rumors that may have a significant impact on the company’s stock trading price, nor did it involve the concept of market hot spots.
(IV) other stock price sensitive information.
After verification by the company, the company found no other major events that may have a great impact on the company’s share price, and the company’s directors, supervisors, senior managers, controlling shareholders and actual controllers did not buy or sell the company’s shares during the abnormal fluctuation of the company’s shares.
3、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that up to now, the company has no other matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of science and Innovation Board of Shanghai Stock Exchange or the planning, negotiation, intention and agreement related to such matters, The board of directors has not been informed that the company has information that should be disclosed but not disclosed in accordance with relevant provisions such as the Listing Rules of science and Innovation Board of Shanghai Stock Exchange, which may have a great impact on the trading price of the company’s shares and their derivatives.
4、 Relevant risk tips
The company solemnly reminds investors that Shanghai Securities News, China Securities News, securities times and Securities Daily are the information disclosure newspapers designated by the company, and the website of Shanghai Stock Exchange (www.sse. Com. CN.) Specify an information disclosure website for the company. All information of the company shall be subject to the information published in the above designated media. Please invest rationally and pay attention to investment risks.
5、 Online disclosure documents
Written replies from controlling shareholders and actual controllers
It is hereby announced.
Hangzhou Alltest Biotech Co.Ltd(688606) board of directors January 20, 2022
